La UB participa en un ambicioso consorcio para diseñar fármacos que potencien la respuesta inmunitaria contra el cáncer

by Fundació Bosch i Gimpera

La inmunoterapia oncológica es un tipo de tratamiento que estimula las defensas naturales del cuerpo con el fin de combatir el cáncer. A pesar de que se trata de una de las estrategias más prometed...

Read more

Palobiofarma receives milestone payment from Novartis

by Palobiofarma

The milestone payment is the first from the licensing agreement between the two companies. Under the terms of that agreement, which was signed in September 2015, Novartis has exclusive development and...

Read more

Palobiofarma signs licensing agreement to develop novel adenosine-based immuno-oncology treatments

by Palobiofarma

Under the terms of the agreement Novartis will acquire exclusive global rights to develop, manufacture and commercialize Palobiofarma´s adenosine A2Areceptor antagonist PBF-509, currently entering Ph...

Read more
Subscribe to Directory
Write an Article

Recent News

Tuneable reverse photochromes in the sol...

A new technique allows the design of solid materia...

La Unidad de Chequeos de la Clínica sup...

El estudio realizado sobre una muestra significati...

Highlight

Interview with Dámaso Molero, general m...

by 3P Biopharmaceuticals

Dámaso Molero: “There are great opportunities in Latin America for ...

ORYZON reports results and corporate upd...

by Oryzon Genomics

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage...

Photos Stream